Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback